Long L - Search Results

1

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa.

Jo Y, Jamieson L, Edoka I, Long L, Silal S, Pulliam JRC, Moultrie H, Sanne I, Meyer-Rath G, Nichols BE. Jo Y, et al. Among authors: long l. Open Forum Infect Dis. 2021 Jan 29;8(3):ofab040. doi: 10.1093/ofid/ofab040. eCollection 2021 Mar. Open Forum Infect Dis. 2021. PMID: 33732750 Free PMC article.

2

Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.

Rosen S, Long L, Fox M, Sanne I. Rosen S, et al. Among authors: long l. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):334-44. doi: 10.1097/QAI.0b013e31817ae5ef. J Acquir Immune Defic Syndr. 2008. PMID: 18545151

3

The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa.

Rosen S, Long L, Sanne I. Rosen S, et al. Among authors: long l. Trop Med Int Health. 2008 Aug;13(8):1005-15. doi: 10.1111/j.1365-3156.2008.02114.x. Epub 2008 Jul 8. Trop Med Int Health. 2008. PMID: 18631314 Free article.

4

High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.

Fox MP, Ive P, Long L, Maskew M, Sanne I. Fox MP, et al. Among authors: long l. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):500-6. doi: 10.1097/QAI.0b013e3181bcdac1. J Acquir Immune Defic Syndr. 2010. PMID: 19838128

5

The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa.

Long L, Fox M, Sanne I, Rosen S. Long L, et al. AIDS. 2010 Mar 27;24(6):915-9. doi: 10.1097/QAD.0b013e3283360976. AIDS. 2010. PMID: 20042849

6

Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa.

Larson BA, Brennan A, McNamara L, Long L, Rosen S, Sanne I, Fox MP. Larson BA, et al. Among authors: long l. Trop Med Int Health. 2010 Jun;15 Suppl 1(s1):43-7. doi: 10.1111/j.1365-3156.2010.02511.x. Trop Med Int Health. 2010. PMID: 20586959 Free PMC article.

7

Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.

Rosen S, Larson B, Brennan A, Long L, Fox M, Mongwenyana C, Ketlhapile M, Sanne I. Rosen S, et al. Among authors: long l. PLoS One. 2010 Sep 14;5(9):e12731. doi: 10.1371/journal.pone.0012731. PLoS One. 2010. PMID: 20856821 Free PMC article.

8

Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa.

Larson BA, Brennan A, McNamara L, Long L, Rosen S, Sanne I, Fox MP. Larson BA, et al. Among authors: long l. Bull World Health Organ. 2010 Sep 1;88(9):675-80. doi: 10.2471/BLT.09.068981. Epub 2010 Apr 16. Bull World Health Organ. 2010. PMID: 20865072 Free PMC article.

9

The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data.

Rosen S, Long L, Sanne I, Stevens WS, Fox MP. Rosen S, et al. Among authors: long l. J Int AIDS Soc. 2011 May 15;14:24. doi: 10.1186/1758-2652-14-24. J Int AIDS Soc. 2011. PMID: 21575155 Free PMC article.

10

Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort.

Long L, Brennan A, Fox MP, Ndibongo B, Jaffray I, Sanne I, Rosen S. Long L, et al. PLoS Med. 2011 Jul;8(7):e1001055. doi: 10.1371/journal.pmed.1001055. Epub 2011 Jul 19. PLoS Med. 2011. PMID: 21811402 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,907 results

Search Page

Filters